Abstract:Chimeric antigen receptors (CAR)-T cells are genetically engineered T-lymphocytes redirected with a predefined specificity to any target antigen, in a non-HLA restricted manner, therefore combining antibody-type specificity with effector T-cell function. This strategy was developed some thirty years ago, after extensive work established the key role of the immune system against cancer. The first-engineered T-cell with chimeric molecule was designed in 1993 by Israeli immunologist Zelig Eshhar. Since then, several modifications took place, including the addition of co-stimulatory domain, to further improve CAR-T cell anti-tumor potency. The first clinical application of CAR-T cell was done in Rotterdam in 2005 for metastatic renal cell carcinoma and simultaneously at the National Cancer Institute (NCI) for metastatic ovarian cancer. These pioneered studies failed to demonstrate a therapeutic benefit, but warning emerged concerning their safety of use. The real clinical success came with anti-CD19 CAR-T cells, used since 2009 by Steven Rosenberg at the NCI in a patient with refractory follicular lymphoma and in 2011 by Carl June and David Porter from the University of Pennsylvania in patients with chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia. From that time, large centers in North America have embarked in several early phase and pivotal trials that have demonstrated unprecedent response rate in heavily pretreated chemo refractory patient with B-cell malignancies. Theses clinical success have led to the approval of three anti-CD19 CAR-T cells products for the management of B-cell malignancies in the United States and in Europe as of December 2020.

CAR T cells: Building on the CD19 paradigm

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T cells for treating autoimmune diseases

Driving CAR T-cells forward

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

CAR T‐cell therapy: Full speed ahead

CAR T Cells: A Snapshot on the Growing Options to Design a CAR

Engineered T Cells: CAR T Cell Therapy and Beyond

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR T therapy beyond cancer: the evolution of a living drug

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

CAR T-Cell Therapy: Progress and Prospects

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Engineering Enhanced CAR T-cells for Improved Cancer Therapy.

Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

CAR-T cells, from principle to clinical applications